Swallowing is an act requiring complex sensorimotor integration. Using a variety of methods first used to study limb physiology, initial efforts to study swallowing have yielded information that multiple cortical and subcortical regions are active participants. Not surprisingly, the regions activated appear to overlap those involved in both oral and nonoral motor behaviors. This review offers a perspective that considers the supranuclear control of swallowing in light of these physiological similarities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00455-009-9249-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functional connectivity patterns among clinical variants of progressive supranuclear palsy.
Alzheimers Dement
December 2024
Mayo Clinic, Rochester, MN, USA
Background: Progressive supranuclear palsy (PSP) can present with different clinical variants which show distinct, but partially overlapping, patterns of neurodegeneration and tau deposition in a PSP network of regions, including cerebellar dentate, superior cerebellar peduncle, midbrain, thalamus, basal ganglia, and frontal lobe. We sought to determine whether disruptions in functional connectivity within this PSP network measured using resting‐state functional MRI (rs‐fMRI) differed between PSP‐Richardson’s syndrome and the cortical and subcortical variants of PSP.
Method: Structural MRI and rs‐fMRI scans were collected for 40 PSP‐RS, 24 PSP‐cortical (12 speech and language; 10 corticobasal syndrome; 2 frontal) and 36 PSP‐subcortical (18 parkinsonism; 11 progressive gait freezing; 6 postural instability; 1 oculomotor) participants who met the Movement Disorder Society PSP clinical criteria (Table 1).
Voxel‐wise Florzolotau (APN‐1607) Tau PET Covariance Patterns in Alzheimer’s Disease and Progressive Supranuclear Palsy.
Alzheimers Dement
December 2024
Medical Center ‐ University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Baden‐Wuerttemberg, Germany
Background: Florzolotau (APN‐1607) tau‐PET has shown distinct patterns of binding in patients with AD and 4‐repeat tauopathies. We aimed to establish disease‐specific tau covariance patterns in AD and PSP/CBS and validate them as user‐independent quantitative biomarkers for reference‐region‐free evaluation of tau‐PET in an independent clinical cohort.
Method: We analyzed Florzolotau PET data from four different cohorts.
Solving synaptic PET‐biomarker puzzle in Alzheimer's and other tauopathies with UCB‐J.
Alzheimers Dement
December 2024
Karolinska Institutet, Stockholm, Sweden
Background: Synaptic loss is an eminent feature of tauopathies. The recently developed novel SV2A PET‐tracer UCB‐J has shown great promise in tracking synaptic loss in tauopathies. However, there have been discrepancies between the in vivo findings and a lack of mechanistic insight.
View Article and Find Full Text PDFInvestigating retrotransposon‐derived eccDNA as a source of innate immune activation in tauopathy.
Alzheimers Dement
December 2024
Center for Alzheimer’s Disease Research, Providence, RI, USA
Background: Retrotransposon‐derived extrachromosomal circular DNA (eccDNA) was extracted and sequenced from brains with Alzheimer’s disease, progressive supranuclear palsy, or healthy controls. Retrotransposon‐derived DNA was visualized outside of the nucleus in these phenotypes with phospho‐STING. were used as a model to study extranuclear retrotransposon DNA.
View Article and Find Full Text PDFVoxel‐wise Florzolotau (APN‐1607) Tau PET Covariance Patterns in Alzheimer’s Disease and Progressive Supranuclear Palsy.
Alzheimers Dement
December 2024
Medical Center ‐ University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Baden‐Wuerttemberg, Germany
Background: Florzolotau (APN‐1607) tau‐PET has shown distinct patterns of binding in patients with AD and 4‐repeat tauopathies. We aimed to establish disease‐specific tau covariance patterns in AD and PSP/CBS and validate them as user‐independent quantitative biomarkers for reference‐region‐free evaluation of tau‐PET in an independent clinical cohort.
Method: We analyzed Florzolotau PET data from four different cohorts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!